These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28212550)

  • 1. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.
    Li CF; Liu TT; Chuang IC; Chen YY; Fang FM; Chan TC; Li WS; Huang HY
    Oncotarget; 2017 Mar; 8(12):19997-20010. PubMed ID: 28212550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors.
    Li CF; Chuang IC; Liu TT; Chen KC; Chen YY; Fang FM; Li SH; Chen TJ; Yu SC; Lan J; Huang HY
    Oncotarget; 2016 Aug; 7(31):49986-49997. PubMed ID: 27366945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
    Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
    World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
    Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
    Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.
    Kondo J; Huh WJ; Franklin JL; Heinrich MC; Rubin BP; Coffey RJ
    J Pathol; 2020 Dec; 252(4):441-450. PubMed ID: 32944951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.
    Guenat D; Deroo O; Magnin S; Chaigneau L; Monnien F; Borg C; Mougin C; Emile JF; Prétet JL
    Oncol Rep; 2017 Mar; 37(3):1671-1681. PubMed ID: 28098915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location.
    Wei YC; Li CF; Yu SC; Chou FF; Fang FM; Eng HL; Uen YH; Tian YF; Wu JM; Li SH; Huang WW; Li WM; Huang HY
    Mod Pathol; 2009 Oct; 22(10):1351-60. PubMed ID: 19648886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
    Li CF; Chen LT; Lan J; Chou FF; Lin CY; Chen YY; Chen TJ; Li SH; Yu SC; Fang FM; Tai HC; Huang HY
    Oncotarget; 2014 Nov; 5(22):11588-603. PubMed ID: 25473890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
    Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
    Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
    [No Abstract]   [Full Text] [Related]  

  • 15. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST.
    Urbini M; Indio V; Tarantino G; Ravegnini G; Angelini S; Nannini M; Saponara M; Santini D; Ceccarelli C; Fiorentino M; Vincenzi B; Fumagalli E; Casali PG; Grignani G; Pession A; Ardizzoni A; Astolfi A; Pantaleo MA
    Genes Chromosomes Cancer; 2019 Sep; 58(9):636-642. PubMed ID: 30887595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rs17084733 variant in the
    Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S
    Epigenetics; 2019 Jun; 14(6):545-557. PubMed ID: 30983504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors.
    Li CF; Liu TT; Wang JC; Yu SC; Chen YY; Fang FM; Li WS; Huang HY
    J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30388854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
    Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
    Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
    Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
    Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.